Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study

被引：0
|
作者：
Papageorgiou, Loula [1 ,2 ]
Fotiou, Despina [3 ]
Van Dreden, Patrick [4 ]
Garderet, Laurent [5 ,6 ]
Dimopoulos, Meletios A. [3 ,7 ]
Elalamy, Ismail [8 ]
Mohty, Mohamad [9 ,10 ,11 ]
Gerotziafas, Grigoris [12 ,13 ]
机构：
[1] Univ Pierre & Marie Curie UPMC, Paris Fac Med Pierre & Marie Curie, Inst Univ Cancerol IUC, Sorbonne Univ,Canc Biol & Therapeut,INSERM U938, Paris, France
[2] Tenon Univ Hosp, AP HP, Dept Haematol, Paris, France
[3] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece
[4] Stago, Clin Res, Gennevilliers, France
[5] Hop Pitie Salpetiere, AP HP, Serv Hematol, Paris, France
[6] Hop St Antoine, Ctr Rech St Antoine, Team Proliferat & Differentiat Stem Cells, Paris, France
[7] Univ Athens, Dept Clin Therapeut, Sch Med, Athens, Greece
[8] Paris 6 Univ, AP HP, Paris 20, France
[9] St Antoine Hosp, Dept Haematol, INSERM UMR 938, Paris, France
[10] St Antoine Hosp, EBMT Paris Study Off CEREST TC, INSERM UMR 938, Paris, France
[11] Univ Paris 06, Paris, France
[12] Sorbonne Univ, Inst Univ Cancerol, INSERM, Canc Haemostasis & Angiogenesis Res Grp, Paris, France
[13] Hop Tenon, AP HP, Thrombosis Ctr, Serv Hematol Biol, Paris, France
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126954
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1913
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A phase I/II study of 166Holmium-DOTMP in combination with high dose chemotherapy and autologous stem cell transplant (ASCT) for the treatment of patients with multiple myeloma (MM)
    Bensinger, W
    Giralt, S
    Eary, J
    Podoloff, D
    Holmberg, L
    Alexanian, R
    Goodman, M
    Serafini, A
    Thoelke, K
    Bryan, JK
    Champlin, R
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 56 - 56
  • [32] Navigating the Changing Multiple Myeloma (MM) Treatment Landscape: Real-World Data on Clinical Practice Patterns in 287 MM Patients Treated in and Outside German DSMM (Deutsche Studiengruppe Multiples Myelom) Study Group Trials
    Gengenbach, Laura
    Reinhardt, Heike
    Ajayi, Stefanie
    Szymaniak-Vits, Magdalena
    Kohler, Martin
    Mueller, Stefan J.
    Dold, Sandra M.
    Hug, Martin J.
    Ruch, Markus
    Boeker, Martin
    Einsele, Hermann
    Duyster, Justus
    Wasch, Ralph
    Engelhardt, Monika
    BLOOD, 2017, 130
  • [33] Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study
    Bahlis, Nizar J.
    Samaras, Christy
    Reece, Donna
    Sebag, Michael
    Matous, Jeffrey
    Berdeja, Jesus G.
    Shustik, Jesse
    Schiller, Gary J.
    Ganguly, Siddhartha
    Song, Kevin
    Seet, Christopher S.
    Acosta-Rivera, Mirelis
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Liu, Hongjuan
    Gentili, Christian
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S494 - S495
  • [34] PROSPECTIVE STUDY OF TREATMENT PATTERN, EFFECTIVENESS, AND SAFETY OF ZOLEDRONIC ACID (ZOL) THERAPY BEYOND 24 MONTHS IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM) OR SOLID TUMOR BONE METASTASIS (STM)
    van den Wyngaert, T.
    Delforge, M.
    Doyen, C.
    Duck, L.
    Wouters, K.
    Delabaye, I.
    Wouters, C.
    Wildiers, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 510 - 510
  • [35] Zoledronic acid (ZOL) treatment (Rx) of ≥2 years in patients (pts) with metastatic bone disease (MBD) or multiple myeloma (MM): Six-month results from the LOTUZ study
    Duck, L.
    Delforge, M.
    Doyan, C.
    Wildiers, H.
    MacDonald, K.
    Lechat, I.
    Abraham, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Rationale and development of an e-health application to deliver patient-centered care during treatment for recently diagnosed multiple myeloma patients: pilot study of the MM E-coach
    Geerts, Paul
    Eijsink, Job
    Moser, Albine
    ter Horst, Peter
    Boersma, Cornelis
    Postma, Maarten
    PILOT AND FEASIBILITY STUDIES, 2023, 9 (01)
  • [37] A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)
    Berdeja, Jesus G.
    Gregory, Tara K.
    Kambhampati, Suman
    Anz, Bertrand M., III
    Tarantolo, Stefano R.
    Meluch, Anthony A.
    Matous, Jeffrey V.
    BLOOD, 2019, 134
  • [38] Rationale and development of an e-health application to deliver patient-centered care during treatment for recently diagnosed multiple myeloma patients: pilot study of the MM E-coach
    Paul Geerts
    Job Eijsink
    Albine Moser
    Peter ter Horst
    Cornelis Boersma
    Maarten Postma
    Pilot and Feasibility Studies, 9
  • [39] Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)
    Manrique, Irene
    Greil, Richard
    Andel, Johannes
    Sormann, Siegfried
    Hartmann, Bernd L.
    Podar, Klaus
    Egle, Alexander
    Petzer, Andreas
    Zojer, Niklas
    Gunsilius, Eberhard
    Ruckser, Reinhard
    Bozic, Boris
    Schmitt, Clemens A.
    Machherndl-Spandl, Sigrid
    Agis, Hermine
    Schreder, Martin
    Wang, Song-Yau
    Willenbacher, Wolfgang
    Krauth, Maria-Theresa
    Tinchon, Christoph
    Fillitz, Michael
    Melchardt, Thomas
    Knop, Stefan
    Paiva, Bruno
    Ludwig, Heinz
    BLOOD, 2021, 138
  • [40] ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC PROGENITORS (T-ALO) IN PATIENTS WITH MULTIPLE MYELOMA (MM). IMPACT OF BIOLOGICAL CHARACTERISTICS TO DIAGNOSIS, TPH DISEASE SITUATION AND TREATMENT LINES. SPANISH MULTICENTRIC RETROSPECTIVE STUDY
    Perez, A.
    De la Rubia, J.
    Rosinol, L.
    Gonzalez, A. J.
    Arnao, M.
    Teruel, Al
    Herrera, I
    Albo, C.
    Vaz, C.
    Krsnik, I
    Bermudez, A.
    Pascual, M. J.
    Encinas, C.
    Cabanas, V
    Jurado, M.
    Gonzalez, S.
    Viguria, M. C.
    Chinea, A.
    Ferra, C.
    Solano, C.
    HAEMATOLOGICA, 2019, 104 : 37 - 38
12345